Adrenocortical carcinoma natural history: Difference between revisions
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
* Weight more than 50 Kg | * Weight more than 50 Kg | ||
* Diameter more than 6.5 cm | * Diameter more than 6.5 cm | ||
* Ki-67/MIB1 labeling index | * Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67) | ||
==References== | ==References== |
Revision as of 15:00, 28 August 2015
Adrenocortical carcinoma Microchapters |
Differentiating Adrenocortical carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Study |
Adrenocortical carcinoma natural history On the Web |
American Roentgen Ray Society Images of Adrenocortical carcinoma natural history |
Risk calculators and risk factors for Adrenocortical carcinoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3]
Overview
Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma stage I-III is approximately 30%. Complication may include metastasis, Conn syndrom and Cushing syndrom
Complications
The following are the complications of Adrenocortical carcinoma:
- Cushing's syndrome
- Conn syndrome
- Hypertension
- Local and distant metastasis
- Paraneoplastic syndrome
- Tumor thrombus formation
Prognosis
Adrenocortical carcinoma, generally, carries a poor prognosis.[1] The five-year disease-free survival rate for a complete resection of a stage I-III is approximately 30%.[1]
The most important prognostic factors are:
- Age of the patient
- Stage of the tumor
- Mitotic activity
- Venous invasion
- Weight more than 50 Kg
- Diameter more than 6.5 cm
- Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)
References
- ↑ 1.0 1.1 Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. PMID 16551738. Free Full Text.